Note: Ingredients listed on restricted chemical lists
EC/CAS
202-966-0/101-68-8
Name of the chemical
4,4’-Methylenediphenyl diisocyanate
Concentration
40,0-<60,0% >=5% >=5% >=5% >=0,1% >=1% >=10% 30,0-<50,0%
EC/CAS
227-534-9/5873-54-1
Name of the chemical
2,4’-Methylenediphenyl diisocyanate
Concentration
>=5% >=5% >=5% >=0,1% >=1% >=10% 0,01-<0,1%
EC/CAS
219-799-4/2536-05-2
Name of the chemical
2,2’-Methylenediphenyl diisocyanate
Concentration
>=5% >=5% >=5% >=0,1% >=1% >=10%
EC/CAS
26447-40-5
Name of the chemical
Methylenediphenyl diisocyanate (see also specific isomers)
Concentration
N/A
General Information
Version
2.0
Revision date
2024-04-27
Product name
ENERLYTE OC 300 Isocyanate
1.2.1 Relevant identified uses
Use at industrial sites Use in flexible foams, thermoplastics and elastomers Formulation & (re)packing of substances and mixtures. Use in polymer production
Emergency telephone
(31) 115 67 2626, 00 41 447 28 2820, 00 32 3575 0330, 070/245.245
Icons in SDS
Company Information
company name
DOW EUROPE GMBH
e-mail address of the competent person responsible for the Safety Data Sheet
SDSQuestion@dow.com
GHS Information
Signal word
DANGER
Hazard Codes
Hazard statements (CLP)
H315, H317, H319, H332, H334, H335, H351, H373
Hazard statements
Code
Statements
H315
Causes skin irritation
Section 2
SECTION 2: Hazards identification
Regulation (EC) No. 1272/2008 Classification of the substance or mixture ™ Trademark of The Dow Chemical Company ("Dow") or an affiliated Page 1 of 33 company of Dow
Signal word
DANGER
Hazard statements
H315 Causes skin irritation. H317 May cause an allergic skin reaction. H319 Causes serious eye irritation. H332 Harmful if inhaled. H334 May cause allergy or asthma symptoms or breathing difficulties if inhaled. H335 May cause respiratory irritation. H351 Suspected of causing cancer. H373 May cause damage to organs through prolonged or repeated exposure.
Precautionary statements
P201 Obtain special instructions before use. P260 Do not breathe mist or vapours. P264 Wash skin thoroughly after handling. P280 Wear protective gloves, protective clothing, eye protection, face protection and/or hearing protection. P304 + P340 IF INHALED: Remove person to fresh air and keep comfortable for breathing. Call a + P312 POISON CENTER/ doctor if you feel unwell. If experiencing respiratory symptoms: Call a POISON CENTER and/or doctor.
Additional information
In the EU, NO, IS, LI and GB "As from 24 August 2023 adequate training is required before industrial or professional use."
Contains
4,4'-methylenediphenyl diisocyanate; 4,4'-Methylenediphenyl Diisocyanate, Polytetramethyleneglycol, Copolymer; Methylenediphenyl diisocyanate, homopolymer; o-(p-isocyanatobenzyl)phenyl isocyanate; Diphenylmethane-2,2'-diisocyanate Page 2 of 33
2.3 Other hazards
This product contains no substances assessed to be PBT or vPvB at levels of 0.1% or higher. Endocrine disrupting properties
Environmental hazards
The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher Human Health The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher
2.1 Classification of the substance or mixture
® ™ Trademark of The Dow Chemical Company ("Dow") or an affiliated Page 1 of 33 company of Dow Classification according to Regulation (EC) No 1272/2008: Acute toxicity - Category 4 - Inhalation - H332 Skin irritation - Category 2 - H315 Eye irritation - Category 2 - H319 Respiratory sensitisation - Category 1 - H334 Skin sensitisation - Category 1 - H317 Carcinogenicity - Category 2 - H351 Specific target organ toxicity - single exposure - Category 3 - H335 Specific target organ toxicity - repeated exposure - Category 2 - H373 For the full text of the H-Statements mentioned in this Section, see Section 16.
